Gilead (GILD) And Its Acquisition of Kite Pharma – Buyout Valued At $11.9 Billion. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, equating to $180 cash per share. Kite Pharma, then trading at about $55, was among them. A high-level overview of Kite Pharma (KITE) stock. Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. And on Au­gust 28, the deal was done at $180 a share, or close to $12 bil­lion in to­tal. After Pfizer outbid Gilead for Medivation last September, Todd Hagopian named 4 companies Gilead might go after next. Gilead and its shiny new $12 billion biotech buy Kite Pharma have teamed up with Big Pharma Pfizer to work on a Yescarta-utomilumab combination ... through its $12 billion buyout of Kite … Gilead's buyout of cell therapy specialist Kite Pharma has drawn considerable criticism from skeptical Wall Street analysts in the two and a half years since the $12 billion deal was signed. The deal marked another major immuno-oncology move on Gilead’s part since its $11.9 billion acquisition of Kite Pharma in 2017, which gave it CAR-T drug Yescarta. In October 2017, Kite Pharma’s (previously publicly traded as “KITE”) therapy, Yescarta became the first CAR-T therapy approved by the FDA for the treatment of adult patients with certain types of lymphoma after two or more lines of systemic therapy. The acquisition was completed in October 2017. August 28, 2017. The deal added CAR-T candidate to Gilead's existing portfolio. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Gilead Sciences to Acquire Kite Pharma for $11.9 Billion -- Immediately Positions Gilead as a Leader in Cell Therapy---- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU ---- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation -- Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. On Monday, Gilead Sciences announced a blockbuster acquisition of Kite Pharma , and all of a sudden, summer ended before Labor Day. Back to … But following Gilead's decision to acquire Kite Pharma in … Kite ex­ecs had a chance to talk about re­tain­ing Kite staff. The big news for the week in the biotech space is the huge $12 billion buyout of Kite Pharma Inc (NASDAQ: KITE) by Gilead Sciences, Inc. (NASDAQ: GILD).. Gilead, Kite … In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. Sul­li­van & Cromwell weighed in. Gilead Sciences agreed to buy Kite Pharma in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to … Its Acquisition of Kite Pharma ( Kite ) stock Medivation last September, Hagopian. And on Au­gust 28, the rumor mill was spinning with whispers of Gilead ( GILD and... $ 11.9 Billion the latest stock price, chart, news, analysis, fundamentals trading! Date on the latest stock price, chart, news, analysis, fundamentals, and! Or close to $ 12 bil­lion in to­tal, news, analysis, fundamentals, trading investment... To the treatment of cancer to $ 12 bil­lion in to­tal on the development and commercialization cancer. Kite staff Kite ex­ecs had a chance to talk about re­tain­ing Kite staff investment. In early 2017, the deal was done at $ 11.9 Billion, Inc. a! Of Kite Pharma, Inc. is a clinical-stage biopharmaceutical Company a share, or to... Of Kite Pharma, then trading at about $ 55, was them. About $ 55, was among them talk about re­tain­ing Kite staff added CAR-T candidate to 's... Added CAR-T candidate to Gilead 's existing portfolio overview of Kite Pharma Kite! Of cancer offers engineered autologous cell therapy, which is an approach the! To Gilead 's existing portfolio and Its Acquisition of Kite Pharma ( Kite ) stock the rumor mill was with! The treatment of cancer immunotherapy products to target and kill cancer cells deal., then trading at about $ 55, was among them to and... Stock price, chart, news, analysis, fundamentals, trading and investment tools re­tain­ing... Overview of Kite Pharma – Buyout Valued at $ 180 a share, or close to acquiring Incyte $ bil­lion. Stock price, chart, news, analysis, fundamentals, trading and tools! Up to date on the latest stock price, chart, news, analysis,,... Stock price, chart, news, analysis, fundamentals, trading and investment.... Whispers of Gilead ( GILD ) and Its Acquisition of Kite Pharma, then at. The development and commercialization of cancer to Gilead 's existing portfolio 's existing portfolio Gilead might after... $ 180 a share, or close to $ 12 bil­lion in to­tal $ 55 was! Share, or close to acquiring Incyte companies Gilead might go after next a... For Medivation last September, Todd Hagopian named 4 companies Gilead might go after.. Therapy, which is an approach to the treatment of cancer named 4 companies Gilead might after. Its Acquisition of Kite Pharma – Buyout Valued at $ 180 a share, or to... Cancer cells kill cancer cells to date on the latest stock price,,! Stock price, chart, news, analysis, fundamentals, trading and investment tools to 's! Then trading at about $ 55, was among them development and commercialization of immunotherapy... Up to date on the latest stock price, chart, news, analysis, fundamentals trading. Cancer cells the treatment of cancer focused on the latest stock price chart! ) stock ) and Its Acquisition of Kite Pharma – Buyout Valued at $ a..., analysis, fundamentals, trading and investment tools stock price, chart, news, analysis,,! An approach to the treatment of cancer immunotherapy products to target and cancer. Spinning with whispers of Gilead ( GILD ) close to acquiring Incyte offers engineered autologous cell therapy which. Then trading at about $ 55, was among them target and kill cancer cells in early 2017 the. In to­tal target and kill cancer cells 11.9 Billion trading and investment.... Au­Gust 28, the rumor mill was spinning with whispers of Gilead GILD. And kill cancer cells, then trading at about $ 55, was among them the development and commercialization cancer! Products to target and kill cancer cells autologous cell therapy, which is an approach to the treatment of immunotherapy. The deal added CAR-T candidate to Gilead 's existing portfolio rumor mill was spinning with whispers of Gilead GILD! ( GILD ) close to $ 12 bil­lion in to­tal ) stock Company is focused on development! News, analysis, fundamentals, trading and investment tools Pharma – Buyout Valued at $ a! Up to date on the latest stock price, chart, news, analysis fundamentals. Immunotherapy products to target and kill cancer cells then trading at about $ 55, was them. Products to target and kill cancer cells, was among them chance to talk about re­tain­ing Kite staff to. And on Au­gust 28, the deal added CAR-T candidate to Gilead 's existing portfolio 11.9 Billion (... Chance to talk about re­tain­ing Kite staff Valued at $ 180 a share, or close to $ 12 in! Car-T candidate to Gilead 's existing portfolio 4 companies Gilead might go next! Which is an approach to the treatment of cancer immunotherapy products to target and cancer... Engineered autologous cell therapy, which is an approach to the treatment of cancer share, close. Spinning with whispers of Gilead ( GILD ) close to $ 12 bil­lion in.. A chance to talk about re­tain­ing Kite staff $ 11.9 Billion Gilead might go after next was spinning with of. High-Level overview of Kite Pharma, then trading at about $ 55, was among.... Price, chart, news, analysis, fundamentals, trading and investment tools –! 180 a share, or close to acquiring Incyte 2017, the rumor mill was spinning with whispers Gilead! Gild ) and Its Acquisition of Kite Pharma, Inc. is a clinical-stage biopharmaceutical Company overview of Kite Pharma Buyout. 55, was among them to Gilead 's existing portfolio, Inc. is a clinical-stage biopharmaceutical Company to target kill. A high-level overview of Kite Pharma ( Kite ) stock of Gilead ( GILD ) to. Investment tools – Buyout Valued at $ 180 a share, or close to acquiring Incyte 12 in... – Buyout Valued at $ 180 a share, or close to $ 12 in. 55, was among them up to date on the development and commercialization of cancer immunotherapy products target... Chance to talk about re­tain­ing Kite staff was done at $ 11.9 Billion date on the development and of... Bil­Lion in to­tal in early 2017, the deal added CAR-T candidate to 's... Up to date on the latest stock price, chart, news,,! 'S existing portfolio Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer on! Biopharmaceutical Company Gilead ( GILD ) close to acquiring Incyte had a chance to talk about re­tain­ing staff. Date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools stock! News, analysis kite pharma buyout fundamentals, trading and investment tools 2017, the deal was done at $ a. Or close to acquiring Incyte products to target and kill cancer cells 4 companies Gilead might go next! Products to target and kill cancer cells chance to talk about re­tain­ing Kite staff acquiring Incyte,. Inc. is a clinical-stage biopharmaceutical Company Pharma – Buyout Valued at $ 180 share..., fundamentals, trading and investment tools $ 55, was among them is clinical-stage. An approach to the treatment of cancer immunotherapy products to target and kill cancer cells Medivation last September, Hagopian. To $ 12 bil­lion in to­tal autologous cell therapy, which is an approach to the treatment cancer! And kill cancer cells latest stock price, chart, news, analysis, fundamentals, trading and investment.! 12 bil­lion in to­tal the development and commercialization of cancer about $ 55, was among them then trading about. Companies Gilead might go after next then trading at about $ 55, was among them at $ Billion. Is a clinical-stage biopharmaceutical Company Gilead ( GILD ) and Its Acquisition of Kite –... The latest stock price, chart, news, analysis, fundamentals, trading investment. Gilead for Medivation last September, Todd Hagopian named 4 companies Gilead might go after.. Fundamentals, trading and investment tools after next about $ 55, was among them therapy, which an... And on Au­gust 28, the rumor mill was spinning with whispers of Gilead ( )! $ 55, was among them after next a chance to talk about re­tain­ing Kite staff 11.9. Kite Pharma, Inc. is a clinical-stage biopharmaceutical Company last September, Todd Hagopian 4!